Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints oncology development head

Dr Fouad Namouni promoted from head of medical

BMS Dr Fouad NamouniBristol-Myers Squibb has promoted Dr Fouad Namouni to oncology development head.

In his new role, Dr Namouni will oversee the development strategy for the pharmaceutical firm's oncology pipeline from early stage development through to commercialisation.

He will remain a member of the research and development leadership team, reporting to chief scientific officer and executive vice president Francis Cuss.

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions in research and development.

On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab). He most recently served as head of medical.

Cuss said: “Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb.

“As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients.

“I am confident that our oncology development programmes will continue to thrive under his leadership.”

27th July 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics